A 4-week, parallel-group, randomized, double-blind, placebo-controlled, adaptive proof of concept study of AQW051 at up to three dose levels for the treatment of patients with findings consistent with mild Alzheimer's disease (AD) or amnestic mild cognitive impairment (amnestic MCI).
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2016
At a glance
- Drugs AQW 051 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Therapeutic Use
- 12 Jun 2009 Actual patient number (54), additional location South Africa added as reported by ClinicalTrials.gov.
- 12 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Jan 2008 New trial record.